Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This study will estimate overall response rate of pemetrexed in poor risk patients with
advanced, metastatic, or recurrent squamous cell carcinoma of the head and neck.